Biomarin to Acquire Amicus for $4.8B

Julie Chang summarizes Biomarin's cash deal for Amicus and its portfolio expansion into Fabry and Pompe disease treatments.

Play episode from 01:15

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!